FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 67 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health Crisis Preparedness Plan MOST POPULAR Junk food marketing restrictions: so near and yet so far December 15, 2022 New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... December 1, 2022 CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research July 13, 2020 Study Adds to Debate about Screening for Melanoma May 4, 2022 Load more HOT NEWS Oral Cancer Taught Me How Much Words Matter Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... The 10 Things That Helped Me Cope With My 2 Cancer... FDA Proposes Rule Prohibiting Menthol Cigarettes
